Important information for pharmacists about Gelnique® — the first and only gel for overactive bladder

Healthcare providers have the option of prescribing a unique gel formulation — Gelnique® (oxybutynin chloride) Gel 10% — to treat patients with overactive bladder (OAB). Gelnique® is marketed by Watson Pharma, Inc.

Gelnique® delivers oxybutynin in an easy-to-use, once-daily topical gel that patients rub onto their skin for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and frequency.1

Efficacy highlights

• Gelnique® has been shown to significantly reduce the number of daily incontinence episodes associated with OAB1,*
• Gelnique® patients with >5 daily episodes at baseline (n=389) experienced a 71% median reduction in incontinence episodes associated with OAB compared with 55.6% for placebo (n=400; P<0.0001)2,*

  –	Median change from baseline in patients with >5 episodes per day: -2.7 for Gelnique®, -2.0 for placebo (P<0.0001)1

• Gelnique® patients with 2-3 daily episodes at baseline (n=85) experienced an 89% median reduction in incontinence episodes associated with OAB compared with 62.5% for placebo (n=86; P=0.0148)2,†

  –	Median change from baseline in patients with 2-3 episodes per day: -2.0 for Gelnique®, -1.3 for placebo (P<0.0053)

How Gelnique® is applied

• Patients can apply Gelnique® after showering in the morning or at night, as long as the time is consistent from day to day
• Patients should be advised to rotate application sites — which include the upper arms/shoulders, thighs, or abdomen — daily

How Gelnique® is supplied

• Gelnique® is available as a 1-month supply of thirty (30) 1-gram unit dose (1.14 mL) sachets contained in a box
• Each sachet contains 10% (100 mg/g) oxybutynin chloride gel

Favorable safety profile*

Gelnique® has a low incidence of bothersome side effects that can make patients stop treatment — such as dry mouth and constipation. Gelnique® is absorbed directly into the bloodstream through the skin and bypasses the gastric system and first-pass metabolism of the liver. Avoiding first-pass metabolism reduces the amount of N-desethyloxybutynin (N-DEO) metabolite in the bloodstream.1 Researchers believe that N-DEO may play a role in the development of some side effects associated with oral oxybutynin, such as dry mouth.12,13

• Most rates of anticholinergic adverse events for Gelnique® were similar to placebo in a clinical trial3:

• No serious adverse events related to treatment were reported1
• The most commonly reported adverse events associated with the use of Gelnique® reported in the phase 3 trial1:

• Most treatment-related adverse events were described as mild or moderate in intensity1
• Only 0.8% of Gelnique®-treated patients discontinued treatment in a clinical trial due to application site reactions, compared with 0.3% for placebo1,3

If you have any questions, please call 1-888-GELNIQUE (1-888-435-6478). On behalf of Watson Pharma, Inc., thank you for your continued support.

Prescribing Information
Frequently Asked Questions (FAQ)
Ordering Information

*	In a phase 3, 12-week, randomized, double-blind, placebo-controlled, parallel-group study comparing Gelnique® (n=389) to placebo (n=400).
†	Results from a post-hoc analysis of the phase 3, 12-week, randomized, double-blind, placebo-controlled, parallel-group study comparing Gelnique® (n=85) to placebo (n=86).